All Stories

  1. L’espace vécu and Its Perturbations in Schizophrenia: Systematic Review and Meta-analysis of Altered Body-Centric Metrics—Personal and Peripersonal Space
  2. Baseline benzodiazepine exposure is associated with greater risk of transition in clinical high-risk for psychosis (CHR-P): a meta-analysis
  3. The temporal dynamics of transition to psychosis in individuals at clinical high-risk (CHR-P) shows negative prognostic effects of baseline antipsychotic exposure: a meta-analysis
  4. Faraway So Close: Schizophrenia and Dissociation From Clinical, Phenomenological, and Ontogenetic Viewpoints
  5. Clinical High Risk for Psychosis (CHR-P) in children and adolescents: a roadmap to strengthen clinical utility through conceptual clarity
  6. Neurodevelopmental Antecedents and Sensory Phenomena in Obsessive Compulsive Disorder: A Systematic Review Supporting a Phenomenological-Developmental Model
  7. Do antidepressants prevent transition to psychosis in individuals at clinical high-risk (CHR-P)? Systematic review and meta-analysis
  8. Vaccine Hesitancy, Anti-Vax, COVID-Conspirationism: From Subcultural Convergence to Public Health and Bioethical Problems
  9. Clinical high risk for psychosis in children and adolescents: A meta-analysis of transition prevalences
  10. From economic crisis and climate change through COVID-19 pandemic to Ukraine war: a cumulative hit-wave on adolescent future thinking and mental well-being
  11. Association between psychosocial interventions and aberrant salience in adolescents with early psychosis: A follow‐up study
  12. (Developmental) Motor Signs: Reconceptualizing a Potential Transdiagnostic Marker of Psychopathological Vulnerability
  13. Antipsychotics in Children and Adolescents at Clinical High Risk for Psychosis
  14. Examining subjective experience of aberrant salience in young individuals at ultra-high risk (UHR) of psychosis: A 1-year longitudinal study
  15. Through the prism of comorbidity: A strategic rethinking of early intervention in obsessive-compulsive disorder
  16. Identifying adolescents in the early stage of psychosis: A screening checklist for referrers
  17. Aberrant salience in first‐episode psychosis: Longitudinal stability and treatment‐response
  18. Letter to the Editor: Skin-Testing for Clones—Pediatric Obsessive Compulsive Disorder with Misidentification Syndrome
  19. Applying Transgenerational Scientific Evidence to the Next Wave of Early Identification Strategies for Psychopathological Risk—Transdiagnostic, Developmental, and Personalized
  20. Individualized Diagnostic and Prognostic Models for Psychosis Risk Syndromes: Do Not Underestimate Antipsychotic Exposure
  21. Reply to: Individualized Diagnostic and Prognostic Models for Psychosis Risk Syndromes: Do Not Underestimate Antipsychotic Exposure
  22. Subjective experience of aberrant salience in young people at Ultra-High Risk (UHR) for psychosis: a cross-sectional study
  23. Editorial Perspective: Psychosis risk in adolescence – outcomes, comorbidity, and antipsychotics
  24. Along the fringes of Agency: neurodevelopmental account of the obsessive mind
  25. Negative Prognostic Effect of Baseline Antipsychotic Exposure in Clinical High Risk for Psychosis (CHR-P): Is Pre-Test Risk Enrichment the Hidden Culprit?
  26. ANHEDONIA IN THE PSYCHOSIS RISK SYNDROME: STATE AND TRAIT CHARACTERISTICS
  27. Towards a phenomenological and developmental clinical staging of the mind with psychosis
  28. Early intervention in psychiatry through a developmental perspective
  29. Coronavirus Disease 2019 and Effects of School Closure for Children and Their Families
  30. The Self in the Spectrum: A Meta-analysis of the Evidence Linking Basic Self-Disorders and Schizophrenia
  31. Antipsychotic treatment in clinical high risk for psychosis: Protective, iatrogenic or further risk flag?
  32. Familiarity for Serious Mental Illness in Help-Seeking Adolescents at Clinical High Risk of Psychosis
  33. Editorial Perspective: Rethinking child and adolescent mental health care after COVID‐19
  34. Overcoming the gap between child and adult mental health services: The Reggio Emilia experience in an early intervention in psychosis program
  35. Attenuated Psychosis Syndrome or Pharmacologically Attenuated First-Episode Psychosis?
  36. Negative symptom dimensions in first episode psychosis: Is there a difference between schizophrenia and non‐schizophrenia spectrum disorders?
  37. Meta-analyzing the prevalence and prognostic effect of antipsychotic exposure in clinical high-risk (CHR): when things are not what they seem
  38. Psychological Support to the Community During the COVID-19 Pandemic: Field Experience in Reggio Emilia, Northern Italy
  39. Managing COVID‐19‐related psychological distress in health workers: Field experience in northern Italy
  40. Looking at Intergenerational Risk Factors in Schizophrenia Spectrum Disorders: New Frontiers for Early Vulnerability Identification?
  41. Assessing aberrant salience in young community help‐seekers with early psychosis: The approved Italian version of the Aberrant Salience Inventory
  42. Childhood schizotypal features vs. high-functioning autism spectrum disorder: Developmental overlaps and phenomenological differences
  43. Hey teachers! Do not leave them kids alone! Envisioning schools during and after the coronavirus (COVID-19) pandemic
  44. Advances in early identification of children and adolescents at risk for psychiatric illness
  45. Subjective experience of social cognition in young people at Ultra-High Risk of psychosis: a 2-year longitudinal study
  46. Disembodiment and schizophrenia: Looking at the motor roots of minimal self disorders in a developmental perspective
  47. Developmental Psychotic Risk: Toward a Neurodevelopmentally Informed Staging of Vulnerability to Psychosis
  48. Suicide risk in young people at Ultra-High Risk (UHR) of psychosis: Findings from a 2-year longitudinal study
  49. Suicidal thinking and behaviours in First Episode Psychosis: Findings from a 3‐year longitudinal study
  50. Letter to the editor: Evidence on school closure and children’s social contact: useful for coronavirus disease (COVID-19)?
  51. Anhedonia in young people with first episode psychosis: a longitudinal study
  52. Subjective experience of social cognition in adolescents at ultra-high risk of psychosis: findings from a 24-month follow-up study
  53. Overlooking the transition elephant in the ultra-high-risk room: are we missing functional equivalents of transition to psychosis?
  54. Obsessively thinking through the schizophrenia spectrum: Disentangling pseudo-obsessive schizophrenia from OCD
  55. Impaired Corollary Discharge in Psychosis and At-Risk States: Integrating Neurodevelopmental, Phenomenological, and Clinical Perspectives
  56. Developmental dynamic interplay between executive functions and psychotic risk
  57. The “Reggio Emilia At‐Risk Mental States” program: A diffused, “liquid” model of early intervention in psychosis implemented in an Italian Department of Mental Health
  58. Anhedonia in adolescents at ultra-high risk (UHR) of psychosis: findings from a 1-year longitudinal study
  59. Social dysfunction in preclinical, at risk stages of psychosis: A developmental view
  60. Suicidal Thinking and Behavior in Adolescents at Ultra‐High Risk of Psychosis: A Two‐year Longitudinal Study
  61. Intruding Thoughts: Between Obsessions and Hallucinations
  62. Uncanny Mirroring: A Developmental Perspective on the Neurocognitive Origins of Self-Disorders in Schizophrenia
  63. Clinical high risk for psychosis in childhood and adolescence: findings from the 2-year follow-up of the ReARMS project
  64. Considerations on Retrospective Identification and Classification of Learning Disabilities
  65. Polygenic Risk Score and the (neuro)developmental ontogenesis of the schizophrenia spectrum vulnerability phenotypes
  66. Rethinking the Psychosis Threshold in Clinical High Risk
  67. Calculation of the sound field due to circular rigid and resilient disks using spherical expansions.
  68. Motor Impairment and Developmental Psychotic Risk: Connecting the Dots and Narrowing the Pathophysiological Gap
  69. Clinical Implications of Slower Cognitive Growth in the Psychosis Spectrum
  70. Editorial Perspective: From schizophrenia polygenic risk score to vulnerability (endo‐)phenotypes: translational pathways in child and adolescent mental health
  71. A research framework to isolate visuospatial from childhood motor coordination phenotypes
  72. 28.2 DISORDERS OF THE EMBODIED SELF IN SCHIZOPHRENIA: AT THE CROSSROAD BETWEEN DEVELOPMENT AND PSYCHOPATHOLOGY
  73. Screening for psychosis risk among help‐seeking adolescents: Application of the Italian version of the 16‐item prodromal questionnaire (iPQ‐16) in child and adolescent neuropsychiatry services
  74. Corollary Discharge and Psychosis—Origin of the Model—Reply
  75. Stably positive Lyapunov exponents for symplectic linear cocycles over partially hyperbolic diffeomorphisms
  76. The Italian Version of the Brief 21-Item Prodromal Questionnaire: Field Test, Psychometric Properties and Age-Sensitive Cut-Offs
  77. Corollary Discharge, Self-agency, and the Neurodevelopment of the Psychotic Mind
  78. Internet of Things as a means to improve agricultural sustainability
  79. Architecture of change: rethinking child and adolescent mental health
  80. Rethinking Social Agent Representation in the Light of Phenomenology
  81. The dark side of dopaminergic therapies in Parkinson’s disease: shedding light on aberrant salience
  82. Schizophrenia polygenic risk score and psychotic risk detection
  83. Developmental Coordination Disorder Plus Oculomotor and Visuospatial Impairment as Neurodevelopmental Heralds of Psychosis Proneness
  84. Cognitive Clusters in Specific Learning Disorder
  85. Detecting dysexecutive syndrome in neurodegenerative diseases: are we using an appropriate approach and effective diagnostic tools?
  86. Definition of a visuospatial dimension as a step forward in the diagnostic puzzle of nonverbal learning disability
  87. Cortical thickness in de novo patients with Parkinson disease and mild cognitive impairment with consideration of clinical phenotype and motor laterality
  88. Migraine features in migraineurs with and without anxiety–depression symptoms: A hospital-based study
  89. Concomitant development of hypersexuality and delusional jealousy in patients with Parkinson's disease: A case series
  90. WISC-IV Intellectual Profiles in Italian Children With Specific Learning Disorder and Related Impairments in Reading, Written Expression, and Mathematics
  91. A pilot psychometric study of aberrant salience state in patients with Parkinson’s disease and its association with dopamine replacement therapy
  92. Mild Depressive Symptoms are Associated With Enhanced Affective Theory of Mind in Nonclinical Adult Women
  93. Progression of brain atrophy in the early stages of Parkinson's disease: A longitudinal tensor-based morphometry study in de novo patients without cognitive impairment
  94. Validation and attempts of revision of the MDS-recommended tests for the screening of Parkinson's disease dementia
  95. Diagnosis of possible Mild Cognitive Impairment in Parkinson's disease: Validity of the SCOPA-Cog
  96. The development of delusion revisited: A transdiagnostic framework
  97. A Single-Center, Cross-Sectional Prevalence Study of Impulse Control Disorders in Parkinson Disease
  98. Affective theory of mind in patients with Parkinson's disease
  99. Reply: Dopamine agonists and delusional jealousy in Parkinson's disease: A cross‐sectional prevalence study
  100. Corticobasal Syndrome Presenting With Partial Gerstmann’s Syndrome and Digit Agnosia
  101. From Aberrant Salience to Jumping to Conclusions
  102. Progressive Impairment of Decision-Making in Behavioral-Variant Frontotemporal Dementia
  103. Cognitive correlates of negative symptoms in behavioral variant frontotemporal dementia: implications for the frontal lobe syndrome
  104. How Aware Are Migraineurs of Their Triggers?
  105. Validity and metric of MiniMental Parkinson and MiniMental State Examination in Parkinson’s disease
  106. The relationship between motor symptom lateralization and cognitive performance in newly diagnosed drug-naïve patients with Parkinson's disease
  107. Neural and behavioral substrates of subtypes of Parkinson’s disease
  108. Psychometric properties of the Italian version of the Scales for Outcomes in Parkinson�s disease-in Parkinson�s disease-Cognition (SCOPA-Cog)
  109. Psychometric properties of the Italian version of the Scales for Outcomes in Parkinson�s disease-in Parkinson�s disease- Cognition (SCOPA-Cog)
  110. Diagnosis, assessment and management of delusional jealousy in Parkinson’s disease with and without dementia
  111. Triggers in Allodynic and Non‐Allodynic Migraineurs. A Clinic Setting Study
  112. Acute and chronic cognitive effects of levodopa and dopamine agonists on patients with Parkinson’s disease: a review
  113. Prefrontal cortex, dopamine, and jealousy endophenotype
  114. Behavioral and Psychological Symptoms of Dementia: Factor Analysis and Relationship with Cognitive Impairment
  115. Alteration of affective Theory of Mind in amnestic mild cognitive impairment
  116. Dopamine agonists and delusional jealousy in Parkinson's disease: A cross‐sectional prevalence study
  117. Mild cognitive impairment in De Novo Parkinson's disease according to movement disorder guidelines
  118. Mild affective symptoms in de novo Parkinson's disease patients: relationship with dopaminergic dysfunction
  119. Alexithymia Is Associated With Impulsivity in Newly-Diagnosed, Drug-Naïve Patients With Parkinson’s Disease: An Affective Risk Factor for the Development of Impulse-Control Disorders?
  120. Cognitive and affective Theory of Mind in neurodegenerative diseases: Neuropsychological, neuroanatomical and neurochemical levels
  121. Relationship Between Neuropsychiatric Symptoms and Cognitive Performance in De Novo Parkinson’s Disease
  122. The “Closing-In” Phenomenon in Parkinson’s Disease Dementia and Lewy-Body Dementia
  123. Affective symptoms and cognitive functions in Parkinson's disease
  124. Orbital and ventromedial prefrontal cortex functioning in Parkinson’s disease: Neuropsychological evidence
  125. Impulse control disorders in Parkinson’ disease: the role of personality and cognitive status
  126. Mild cognitive impairment and cognitive-motor relationships in newly diagnosed drug-naive patients with Parkinson's disease
  127. Impairment of Affective Theory of Mind in Corticobasal Degeneration
  128. Personality traits in patients with Parkinson’s disease: assessment and clinical implications
  129. Iowa gambling task in de novo Parkinson's disease: A comparison between good and poor performers
  130. Event-Based Prospective Memory in Newly Diagnosed, Drug-Naive Parkinson's Disease Patients
  131. Mild cognitive impairment and cognitive reserve in Parkinson’s disease
  132. Impulsivity Is Associated With Decision-Making Deficits in De-Novo Parkinson's Disease
  133. Theory of Mind in Parkinson's disease
  134. The neuropsychological correlates of pathological lying: evidence from behavioral variant frontotemporal dementia
  135. Decision-Making Impairment May Precede Limb Apraxia in Corticobasal Degeneration
  136. Impulsivity and compulsivity in drug‐naïve patients with Parkinson's disease
  137. Alexithymia Is Associated with Depression in de novo Parkinson’s Disease
  138. From Narcissistic Personality Disorder to Frontotemporal Dementia: A Case Report
  139. The association between motor subtypes and alexithymia in de novo Parkinson’s disease
  140. Iowa Gambling Task in Parkinson's Disease
  141. Decision making in de novo Parkinson's disease
  142. Out-of-Control Sexual Behavior in an Orbitofrontal Cortex-Damaged Elderly Patient
  143. Orbitofrontal cortex-related executive functions in children and adolescents: their assessment and its ecological validity
  144. Out-of-Control Sexual Behavior in an Orbitofrontal Cortex-Damaged Elderly Patient
  145. Decision-Making Impairment in a Patient With New Concomitant Diagnoses of Parkinson's Disease and HIV
  146. Decision-Making Impairment in a Patient With New Concomitant Diagnoses of Parkinson’s Disease and HIV
  147. Gestural buffer impairment in early onset Corticobasal Degeneration: a single-case study